Epithalon is being studied for its potential anti-ageing effects, including supporting telomere length and cellular health
Retatrutide, triple GIP/GLP-1/glucagon agonist Retatrutide (development code LY3437943, Eli Lilly) is an investigational single-peptide compound that simultaneously activates three receptors: GIP, GLP-1 and the glucagon receptor (GCGR)
A phase 2, double-blind, placebo-controlled trial randomized patients with moderate-severe PDPN to subcutaneous fulranumab or placebo
Mitochondrial and fatty changes in hepatocytes of patients with Wilsons disease
and prosecution histories showing terminal disclaimers linking the expiry of secondary patents to earlier-expiring parents
Conversely, THC in cannabis is well known to stimulate appetite, potentially counteracting tirzepatide's appetite-suppressing effects